Judo Bio
Latest round
- Series A
Last raised
- Jul 2024
Total raised
- $45M
Investors
- 7
About Judo Bio
Established in 2021 and based in Massachusetts, US, Judo Bio Inc. is a biotechnology company that develops oligonucleotide medicines targeting kidney diseases. As of 2024, Rajiv Patni is leading the firm as CEO. Judo Bio's primary offering includes ligand-siRNA conjugates that enable receptor-mediated uptake in the kidneys. This novel technology leverages the kidney's physiology, particularly its recycling receptors, for the precision of drug delivery. The company's pipeline focuses on targeting solute carrier proteins within the nephron, making strides in developing treatments for both systemic and renal conditions.
Who invested in Judo Bio
7 investors across 2 rounds
See all investors in Judo Bio
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Judo Bio
Who invested in Judo Bio?
Judo Bio has 7 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Judo Bio raised?
Judo Bio has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Judo Bio last raise money?
Judo Bio's most recent round on record is a Series A, in Jul 2024.
What does Judo Bio do?
Established in 2021 and based in Massachusetts, US, Judo Bio Inc.
Where is Judo Bio headquartered?
Judo Bio is headquartered in Cambridge, US.
Which VCs invest in companies like Judo Bio?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Judo Bio's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Judo Bio? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.